

Table E2. Mean HCVA of participants in RENEW at baseline and weeks 24 and 32

Mean (SD) HCVA, Letters	Placebo (n = 36)		Opicinumab (n = 33)	
	Affected Eye	Fellow Eye	Affected Eye	Fellow Eye
Baseline ^a	44.4 (19.9)	58.3 (8.1)	43.0 (22.0)	60.4 (6.5)
Week 24	55.9 (10.0)	60.7 (6.3)	51.9 (17.5)	61.3 (7.1)
Week 32 ^a	55.3 (11.3)	60.5 (7.2)	54.0 (16.9)	61.2 (7.8)

HCVA, high-contrast visual acuity.

^aOpicinumab, n = 32.